Management of Asymptomatic Patients with Elevated GGT and Grade 3 Fatty Liver on Statin Therapy

Risk Stratification and Diagnosis

The American Gastroenterological Association recommends calculating the FIB-4 score using standard laboratory values to risk-stratify for advanced liver fibrosis, determining whether the patient can be managed in primary care or requires hepatology referral 1
For patients with FIB-4 <1.3 (or <2.0 if age >65 years), the risk for advanced fibrosis is low, and management in primary care with repeat FIB-4 in 2-3 years is recommended 1
For patients with FIB-4 1.3-2.67, the risk is indeterminate, and liver stiffness measurement via transient elastography (FibroScan) is recommended 1, 2
For patients with FIB-4 >2.67, the risk for advanced fibrosis is high, and referral to hepatology for specialized evaluation is recommended 1, 2

A comprehensive metabolic panel and complete blood count should be obtained to calculate FIB-4 and assess liver synthetic function, as recommended by the American Gastroenterological Association 1
Systematic screening for alcohol use with the AUDIT questionnaire is recommended, as alcohol causes 75% of elevated GGT cases and daily consumption >60g elevates GGT 3
An extended liver screen to exclude alternative diagnoses, including hepatitis C antibody, hepatitis B surface antigen, autoimmune markers, and ferritin, is recommended 1, 3

For low-risk patients (FIB-4 <1.3), lifestyle intervention targeting 7-10% weight loss, optimization of metabolic comorbidities, and repeat FIB-4 annually or in 2-3 years is recommended 1, 2
For intermediate-risk patients (FIB-4 1.3-2.67), liver stiffness measurement via transient elastography (FibroScan) is recommended, and management is based on the results 1
For high-risk patients (FIB-4 >2.67 or liver stiffness >12 kPa), referral to hepatology for consideration of liver biopsy or magnetic resonance elastography, screening for hepatocellular carcinoma, and multidisciplinary management is recommended 1, 2